Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Non-Small-Cell Lung 20Neoplasms 18Breast Neoplasms 18Glioblastoma 17Esophageal Squamous Cell Carcinoma 16Rectal Neoplasms 15Lung Neoplasms 15Esophageal Neoplasms 15Head and Neck Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 10Glioma 10Nasopharyngeal Carcinoma 8Stomach Neoplasms 7Radiation Injuries 7Oropharyngeal Neoplasms 7Brain Neoplasms 7Hyperthermia 6Carcinoma, Hepatocellular 6Astrocytoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Oligodendroglioma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4

Interventions

Leucovorin 2Fluorouracil 2Cetuximab 2Bevacizumab 2spartalizumab 1sintilimab 1Radiotherapy 1Radiation Dose Hypofractionation 1Oxaliplatin 1Irinotecan 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Locally Recurrent Rectal Cancer × Radiotherapy × Clear all
NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Fudan University

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡